Other equities research analysts have also issued research reports about the stock. Mizuho set a $90.00 target price on shares of CVS Health and gave the stock a buy rating in a report on Tuesday, October 24th. Oppenheimer reaffirmed a buy rating and issued a $95.00 price objective on shares of CVS Health in a research report on Monday, October 9th. SunTrust Banks set a $85.00 price objective on shares of CVS Health and gave the stock a buy rating in a research report on Thursday, October 12th. Cowen set a $86.00 price objective on shares of CVS Health and gave the stock a buy rating in a research report on Sunday, October 29th. Finally, Needham & Company LLC raised shares of CVS Health from a hold rating to a buy rating and lifted their price objective for the stock from $69.02 to $79.00 in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $86.35.
Shares of CVS Health (NYSE:CVS) traded down $0.86 during trading hours on Monday, hitting $70.83. 12,603,917 shares of the company’s stock were exchanged, compared to its average volume of 6,844,036. CVS Health has a 1-year low of $66.45 and a 1-year high of $84.72. The stock has a market cap of $76,095.96, a PE ratio of 13.16, a P/E/G ratio of 1.29 and a beta of 0.89. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.
In other CVS Health news, COO Jonathan C. Roberts sold 85,743 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the completion of the transaction, the chief operating officer now directly owns 119,555 shares in the company, valued at $9,939,802.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the transaction, the chief financial officer now owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 714,125 shares of company stock valued at $58,119,381. Company insiders own 0.61% of the company’s stock.
A number of large investors have recently bought and sold shares of CVS. Fieldpoint Private Securities LLC grew its holdings in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 1,000 shares in the last quarter. Wealthcare Advisory Partners LLC grew its holdings in shares of CVS Health by 330.3% in the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 991 shares during the period. Arcadia Investment Management Corp MI grew its holdings in shares of CVS Health by 119.6% in the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after purchasing an additional 726 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in shares of CVS Health in the second quarter valued at about $119,000. Finally, TB Alternative Assets Ltd. purchased a new stake in shares of CVS Health in the second quarter valued at about $121,000. Institutional investors own 82.24% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “CVS Health (CVS) Given a $77.00 Price Target by Robert W. Baird Analysts” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/05/cvs-health-cvs-given-a-77-00-price-target-by-robert-w-baird-analysts.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.